Skip to main content
SpringerLink
Log in

Immunotherapy for clinically isolated syndrome? Not necessarily...

  • Viewpoint
  • Published:

From Nature Clinical Practice Neurology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Frohman EM et al. (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63: 614–619

    Article  CAS  Google Scholar 

  2. Comi G and Martino G (2006) MS treatment: new perspectives. Clin Neurol Neurosurg 108: 339–345

    Article  Google Scholar 

  3. Siva A (2006) The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 108: 333–338

    Article  Google Scholar 

  4. De Stefano N et al. (2006) Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis. Ann Neurol 59: 634–639

    Article  Google Scholar 

  5. Haghighi S et al. (2004) Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 109: 97–99

    Article  CAS  Google Scholar 

  6. Jacobs LD et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343: 898–904

    Article  CAS  Google Scholar 

  7. Comi G et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 357: 1576–1582

    Article  CAS  Google Scholar 

  8. Kappos L et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242–1249

    Article  CAS  Google Scholar 

  9. Pittock SJ et al. (2006) Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol 63: 611–614

    Article  Google Scholar 

  10. Fillipini G and Ebers G (2007) Multiple sclerosis: critical review of evidence for each question. In Evidence-based Neurology: Management of Neurological Disorders, 221–233 (Eds Candelise L. et al.) Oxford: Blackwell BMJ Books

    Chapter  Google Scholar 

  11. Kappos L et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370: 389–397

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Department of Neurology, Istanbul University Cerrahpaşa School of Medicine Cerrahpaşa, 34098 Istanbul, Turkey asiva@turk.net

Authors and Affiliations

  1. A Siva is Professor of Neurology and Head of the Clinical Neuroimmunology Unit in the Neurology Department, Cerrahpaşa School of Medicine, Istanbul University, Istanbul, Turkey.,

    Aksel Siva

Authors
  1. Aksel Siva
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siva, A. Immunotherapy for clinically isolated syndrome? Not necessarily.... Nat Rev Neurol 4, 236–237 (2008). https://doi.org/10.1038/ncpneuro0774

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0774

  • Springer Nature Limited

Search

Navigation